Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kevzara

- PMLiVE

WHO unveils new initiative to halt spread of invasive malaria vector in Africa

Anopheles stephensi thrives in urban settings, where 40% of the population in Africa live

- PMLiVE

InflaRx seeks FDA authorisation for vilobelimab for critically ill COVID-19 patients

A phase 3 study showed that the antibody reduced the all-cause mortality rate after 28 days

- PMLiVE

WHO and ILO call for ‘concrete actions’ to address mental health issues at work

An estimated 12 billion work days are lost annually due to depression and anxiety, WHO reports

- PMLiVE

Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint

Ensitrelvir reduced the time taken to resolve five key symptoms

- PMLiVE

WHO reports warnings of ‘COVID-19 complacency’ from countries tracking global vaccine roll-out

Vaccination rates in low-income countries stand at 19% compared to almost 75% in high-income countries

- PMLiVE

Pfizer and BioNTech seek FDA authorisation for COVID-19 booster for children

An application will also be submitted to the European Medicines Agency to extend the marketing authorisation for this age group

- PMLiVE

WHO announces recommended 2023 flu vaccines for southern hemisphere

The constantly evolving nature of influenza viruses requires frequent reformulation of vaccines

- PMLiVE

COVID-19 linked to long-term neurologic disorders in new US study

Those infected with the virus had a 77% higher risk of developing memory problems versus control groups

- PMLiVE

Valneva actively discussing second-generation COVID-19 vaccine with prospective partner

The company also plans to send the remaining stocks of its current COVID-19 vaccine to international markets

- PMLiVE

Pfizer to supply 6 million Paxlovid treatments to low- and middle-income countries

Eligible countries will be offered treatment courses according to Pfizer’s tiered pricing approach

- PMLiVE

AstraZeneca’s COVID-19 treatment granted EC approval

Evusheld significantly reduced risk of severe COVID-19 or death in a phase 3 trial

- PMLiVE

AstraZeneca’s COVID-19 treatment receives CHMP recommendation for use in EU

Evusheld provided statistically significant protection against progression to severe COVID-19 or death

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links